4 terminated, 2 completed, 1 active not recruiting, 1 recruiting. 8 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 4, Completed 2, Active not recruiting 1, Recruiting 1 |
| Phase 3 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow ravulizumab: new trials by email Literature Review of ravulizumab trials Research Report on ravulizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders Ravulizumab - Preeclampsia | Phase 2 | Recruiting | Mayo Clinic | 14 | 2027-04-01 | 2026-10-22 |
| Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD Ravulizumab - Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 12 | 2022-06-23 | 2026-06-24 |
| BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy Eculizumab, Ravulizumab, BCX9930 - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Terminated | BioCryst Pharmaceuticals | 12 | 2021-12-06 | 2025-03-07 |
| Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis Ravulizumab, Placebo - Dermatomyositis | Phase 2 / Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 38 | 2021-11-19 | 2025-07-09 |
| Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ravulizumab, Placebo, Background Therapy - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 123 | 2021-01-19 | 2026-01-22 |
| A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) BCX9930, Eculizumab, Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 2 | Terminated | BioCryst Pharmaceuticals | 19 | 2020-12-18 | 2025-04-13 |
| Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria, PNH | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 26 | 2016-01-04 | 2023-01-04 |
| Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) ALXN1210 - PNH | Phase 1 / Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2015-11-12 | 2022-05-16 |
Hemoglobinuria, Paroxysmal (4) · Dermatomyositis (1) · Glomerulonephritis (1) · Glomerulonephritis, IGA (1) · Hemolysis (1) · Lupus Nephritis (1) · Neuromyelitis Optica (1) · Pre-Eclampsia (1)
Alexion Pharmaceuticals, Inc. (5) · BioCryst Pharmaceuticals (2) · Mayo Clinic (1)
France (5) · South Korea (5) · Spain (5) · United Kingdom (5) · Italy (4) · United States (4) · Australia (3) · Canada (3) · Germany (3) · Taiwan (3) · Japan (2) · Poland (2) · Austria (1) · Brazil (1) · Hungary (1)
Austin G Kulasekararaj, MBBS, MD (1) · Maria Lourdes Gonzalez Suarez, MD, PhD (1) · Morag Griffin, MBChB (1)
PMID 30171081, PMID 37528520, PMID 39455063
2015 (1)